Eupraxia Pharmaceuticals (EPRX) Other financing activities (2023 - 2026)

Eupraxia Pharmaceuticals (EPRX) has 4 years of Other financing activities data on file, last reported at $113855.0 in Q1 2026.

• On a quarterly basis, Other financing activities rose 742.31% year-over-year to $113855.0 in Q1 2026; TTM through Mar 2026 was $130701.0, a 823.75% increase from a year earlier, with the FY2025 full-year figure at $639597.0, up 89.33% from the prior year.
• Other financing activities for Q1 2026 stood at $113855.0, up from $2697.0 in the prior quarter.
• Over the last five years, Other financing activities for EPRX reached as high as $337184.0 in Q1 2024 and fell as low as -$5.2 million in Q4 2023.
• Historically, Other financing activities has averaged -$644904.6 across 4 years, with a median of $13517.0 in 2025.
• Across the five-year window, Other financing activities sank 95.99% in 2025 and surged 742.31% in 2026, its largest moves.
• Year by year, Other financing activities stood at -$5.2 million in 2023, then soared by 100.01% to $632.0 in 2024, then jumped by 326.74% to $2697.0 in 2025, then jumped by 4121.54% to $113855.0 in 2026.
• Per Business Quant data, the three most recent Other financing activities figures were $113855.0 in Q1 2026, $2697.0 in Q4 2025, and $13517.0 in Q1 2025.